Americans have unofficially made Memorial Day the kickoff of summer, and it’s going to be a hot one for the drug industry. Between now and Labor Day, five companies are looking at FDA decisions that could launch blockbuster drugs, and make a big impact on their bottom lines. First up will be two drugs from Valeant Pharmaceutical Industries (VRX) and Actavis (ACT) that aim to treat the same condition: irritable bowel syndrome with diarrhea (IBS-D).
Charter Communications (CHTR) is close to a deal to buy larger Time Warner Cable (TWC) for $195 a share, according to multiple reports, after the Comcast (CMCSA)-TWC takeover failed due to regulatory opposition. Charter, the No. 3 U.S. cable operator, will pay $100 a share in cash and the rest in stock, for each share of No. 2 TWC, Bloomberg reported on Monday, citing sources. The Financial Times and Reuters later filed similar reports. Both
IBD 50 superstars Avago Technologies (AVGO) and Ulta Beauty (ULTA) report quarterly earnings after the close on Thursday. Here’s a breakdown of what analysts expect: Apple (AAPL) chip supplier Avago Tech’s fiscal Q2 earnings are projected to surge 136% to $2.01 per share — a third straight quarter of triple-digit growth but a slight slowdown from Q1’s 149% gain. Revenue is estimated to climb 133% to $1.63 billion, which is higher than last